Dr. Neal Shore on Treatment of Elderly Patients With mCRPC
Neal Shore, MD, the medical director of Carolina Urologic Research Center, discusses the role for abiraterone in patients with chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC).
The elderly population can be immunocompromised, worsening fatigue, more deconditioning, and they are often already on androgen deprivation therapy (ADT), says Shore.
When selecting therapy, it is important not to exasperate issues that may already exist in elderly patients like fatigue, lack of appetite, or their diminished participation in extracurricular type activities, specifically their physician activity. Some elderly patients may also have challenges in cognitive function. Abiraterone is very safe and well-tolerated in that patient population of elderly patients, says Shore.
